713 related articles for article (PubMed ID: 21920260)
1. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
Byrne RA; Kastrati A; Massberg S; Wieczorek A; Laugwitz KL; Hadamitzky M; Schulz S; Pache J; Fusaro M; Hausleiter J; Schömig A; Mehilli J;
J Am Coll Cardiol; 2011 Sep; 58(13):1325-31. PubMed ID: 21920260
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Jüni P; Schömig A; Windecker S; Kastrati A
Eur Heart J; 2012 May; 33(10):1214-22. PubMed ID: 22447805
[TBL] [Abstract][Full Text] [Related]
3. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A;
EuroIntervention; 2016 Mar; 11(12):1372-9. PubMed ID: 25405657
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
5. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
[TBL] [Abstract][Full Text] [Related]
6. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.
Park KW; Chae IH; Lim DS; Han KR; Yang HM; Lee HY; Kang HJ; Koo BK; Ahn T; Yoon JH; Jeong MH; Hong TJ; Chung WY; Jo SH; Choi YJ; Hur SH; Kwon HM; Jeon DW; Kim BO; Park SH; Lee NH; Jeon HK; Gwon HC; Jang YS; Kim HS
J Am Coll Cardiol; 2011 Oct; 58(18):1844-54. PubMed ID: 22018294
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
[TBL] [Abstract][Full Text] [Related]
8. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724
[TBL] [Abstract][Full Text] [Related]
9. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
10. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
[TBL] [Abstract][Full Text] [Related]
11. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials.
de Waha A; Dibra A; Byrne RA; Ndrepepa G; Mehilli J; Fusaro M; Laugwitz KL; Massberg S; Schömig A; Kastrati A
Circ Cardiovasc Interv; 2011 Aug; 4(4):371-7. PubMed ID: 21791671
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial).
Jensen LO; Thayssen P; Junker A; Maeng M; Tilsted HH; Kaltoft A; Hansen KN; Christiansen EH; Kristensen SD; Ravkilde J; Madsen M; Sørensen HT; Thuesen L; Lassen JF
Am J Cardiol; 2012 Dec; 110(11):1585-91. PubMed ID: 22959714
[TBL] [Abstract][Full Text] [Related]
13. 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.
Jensen LO; Thayssen P; Christiansen EH; Tilsted HH; Maeng M; Hansen KN; Kaltoft A; Hansen HS; Bøtker HE; Krusell LR; Ravkilde J; Madsen M; Thuesen L; Lassen JF;
J Am Coll Cardiol; 2012 Sep; 60(13):1140-7. PubMed ID: 22958957
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.
Jensen LO; Thayssen P; Christiansen EH; Maeng M; Ravkilde J; Hansen KN; Hansen HS; Krusell L; Kaltoft A; Tilsted HH; Berencsi K; Junker A; Lassen JF;
J Am Coll Cardiol; 2016 Feb; 67(7):751-62. PubMed ID: 26892409
[TBL] [Abstract][Full Text] [Related]
15. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
17. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
18. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.
Mahmoudi M; Delhaye C; Wakabayashi K; Ben-Dor I; Gonzalez MA; Maluenda G; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Am J Cardiol; 2011 Jun; 107(12):1757-62. PubMed ID: 21497782
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
